{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:08:24Z","timestamp":1787238504850,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-grade glioma (HGG) is a malignant brain tumor that is common and aggressive in children and adults. In the current medical paradigm, surgery and radiotherapy are the standard treatments for HGG patients. Despite this, the overall prognosis is still very bleak. Studies have shown that platelet-derived growth factor receptor \u03b1 (PDGFRA) is an essential target to treat tumors and inhibiting the activity of PDGFRA can improve the prognosis of HGG. Thus, PDGFRA inhibitors are critical to developing drugs and cancer treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this study was to screen lead compounds and candidate drugs with potential inhibitors against platelet-derived growth factor receptor \u03b1 (PDGFRA) from the drug library (ZINC database) in order to improve the prognosis of patients with high-grade glioma (HGG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In our study, we selected Imatinib as the reference drug. A series of computer-aided technologies, such as Discovery Studio 2019 and Schrodinger, were used to screen and assess potential inhibitors of PDGFRA. The first step was to calculate the LibDock scores and then analyze the pharmacological and toxicological properties. Following this, we docked the small molecules selected in the previous steps with PDGFRA to study their docking mechanism and affinity. In addition, molecular dynamics simulation was used to determine whether the ligand-PDGFRA complex was stable in nature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two novel natural compounds 1 and 2 (ZINC000008829785 and ZINC000013377891) from the ZINC database were found binding to PDGFRA with more favorable interaction energy. Also, they were predicted with less Ames mutagenicity, rodent carcinogenicity, non-developmental toxic potential, and tolerant with cytochrome P450 2D6 (CYP2D6). The dynamic simulation analysis demonstrated that ZINC000008829785-PDGFRA and ZINC000013377891-PDGFRA dimer complex had more favorable potential energy compared with Imatinib, and they can exist in natural environments stably.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ZINC000008829785 and ZINC000013377891 might provide a solid foundation for drugs that inhibit PDGFRA in HGG. In addition to being safe drug candidates, these compounds had important implications for improving drugs targeting PDGFRA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnins.2022.1060012","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T07:37:12Z","timestamp":1672817832000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["New natural compound inhibitors of PDGFRA (platelet-derived growth factor receptor \u03b1) based on computational study for high\u2212grade glioma therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenzhuo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingcheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanwan","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225799","article-title":"Tyrosine kinase inhibitors in adult glioblastoma: An (Un)closed chapter?","volume":"13","author":"Aldaz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/neuonc\/nos217","article-title":"Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.","volume":"14","author":"Alentorn","year":"2012","journal-title":"Neuro Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11060-017-2685-4","article-title":"Prognostic factors for survival in adult patients with recurrent glioblastoma: A decision-tree-based model.","volume":"136","author":"Audureau","year":"2018","journal-title":"J. Neurooncol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672500","article-title":"Early and next-generation KIT\/PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor.","volume":"11","author":"Bauer","year":"2021","journal-title":"Front. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1586\/ern.10.14","article-title":"Anticancer therapies and CNS relapse: Overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability.","volume":"10","author":"Chamberlain","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/362753","article-title":"Platelet-derived growth factor receptor alpha as a marker of mesenchymal stem cells in development and stem cell biology.","volume":"2015","author":"Farahani","year":"2015","journal-title":"Stem Cells Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1073\/pnas.85.10.3435","article-title":"Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: Evidence for more than one receptor class.","volume":"85","author":"Gronwald","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","article-title":"A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.","volume":"141","author":"Helbig","year":"2008","journal-title":"Br. J. Haematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/carcin\/bgi273","article-title":"Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.","volume":"27","author":"Holtkamp","year":"2006","journal-title":"Carcinogenesis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/path.1823","article-title":"Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.","volume":"207","author":"Joensuu","year":"2005","journal-title":"J. Pathol."},{"key":"B11","doi-asserted-by":"crossref","first-page":"65696","DOI":"10.18632\/oncotarget.11602","article-title":"Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.","volume":"7","author":"Koschmann","year":"2016","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","first-page":"19598","DOI":"10.18632\/aging.203371","article-title":"Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury.","volume":"13","author":"Li","year":"","journal-title":"Aging (Albany NY)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"16620","DOI":"10.18632\/aging.203180","article-title":"Computational study on new natural compound agonists of dopamine receptor.","volume":"13","author":"Li","year":"","journal-title":"Aging (Albany NY)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics.","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma.","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ccell.2018.04.004","article-title":"Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY Phase II randomized trial.","volume":"33","author":"Mackay","year":"2018","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2174\/187152012800228805","article-title":"Chemotherapeutic targeting of cell death pathways.","volume":"12","author":"Mansilla","year":"2012","journal-title":"Anticancer Agents Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s11060-018-2907-4","article-title":"Retrospective study of nivolumab for patients with recurrent high grade gliomas.","volume":"139","author":"Mantica","year":"2018","journal-title":"J. Neurooncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1172\/JCI133310","article-title":"Everolimus improves the efficacy of dasatinib in PDGFR\u03b1-driven glioma.","volume":"130","author":"Miklja","year":"2020","journal-title":"J. Clin. Invest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1200\/JCO.2011.35.5677","article-title":"Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.","volume":"29","author":"Paugh","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1215\/15228517-2006-031","article-title":"Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A pediatric brain tumor consortium report.","volume":"9","author":"Pollack","year":"2007","journal-title":"Neuro Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/neuonc\/nop001","article-title":"Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas.","volume":"12","author":"Qu","year":"2010","journal-title":"Neuro Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1021\/ci6004299","article-title":"Validation studies of the site-directed docking program LibDock.","volume":"47","author":"Rao","year":"2007","journal-title":"J. Chem. Inf. Model."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.922928","article-title":"Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine.","volume":"12","author":"Schwark","year":"2022","journal-title":"Front. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"B27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B28","article-title":"Novel diagnostic and therapeutic approaches to malignant glioma.","volume":"141","author":"Weller","year":"2011","journal-title":"Swiss Med. Wkly."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/neuonc\/nos273","article-title":"Standards of care for treatment of recurrent glioblastoma\u2013are we there yet?","volume":"15","author":"Weller","year":"2013","journal-title":"Neuro Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.bmcl.2018.04.030","article-title":"Preliminary in vitro and in vivo investigation of a potent platelet derived growth factor receptor (PDGFR) family kinase inhibitor.","volume":"28","author":"Wilson","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semcancer.2016.02.001","article-title":"Targeting arachidonic acid pathway by natural products for cancer prevention and therapy.","author":"Yarla","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"B32","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.18632\/aging.103986","article-title":"Effective natural inhibitors targeting poly ADP-ribose polymerase by computational study.","volume":"13","author":"Zhong","year":"2021","journal-title":"Aging (Albany NY)"}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2022.1060012\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T07:37:18Z","timestamp":1672817838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2022.1060012\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":32,"alternative-id":["10.3389\/fnins.2022.1060012"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2022.1060012","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"1060012"}}